logo
  

Seagen: CHMP Adopts Positive Opinion For TUKYSA - Quick Facts

Biotechnology company Seagen Inc. (SGEN) said Friday that the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency has adopted a positive opinion for TUKYSA (tucatinib) for the treatment of patients with locally advanced or metastatic HER2-Positive breast cancer.

The CHMP positive opinion recommends the approval of TUKYSA in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer who have received at least 2 prior anti-HER2 treatment regimens.

The CHMP positive opinion will now be considered by the European Commission or EC, which has the authority to approve medicines in the European Union or EU.

TUKYSA is an oral, small molecule tyrosine kinase inhibitor (TKI) of HER2, a protein that contributes to cancer cell growth.

The positive CHMP opinion is based on results of the pivotal trial HER2CLIMB and were published in the New England Journal of Medicine in December 2019.

TUKYSA is approved in the U.S., Canada, Switzerland, Singapore and Australia.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
PepsiCo, Inc. (PEP) has reached an agreement with private equity firm PAI Partners to sell Tropicana, Naked and other select juice brands across North America. The agreement also includes an irrevocable option to sell certain juice businesses in Europe. The combined pre-tax cash proceeds will be approximately... Drug major Eli Lilly And Co. reported Tuesday weak profit in its second quarter, despite higher revenues driven by strong volume across core business and most major geographies. Further, the company trimmed its forecast for fiscal 2021 earnings on a reported basis and margin, while maintained adjusted earnings view above market estimates. The company also tightened full-year revenue forecast. Shares of BMW Group were losing around 5 percent in German trading after the luxury automaker warned Tuesday that its second half-year is likely to be more volatile, affected by supply bottlenecks, high prices for raw materials and a shortage of semiconductors. This was despite reporting strong second-quarter results driven by solid demand.
Follow RTT